Cargando…
Implications of early diagnosis of autosomal dominant polycystic kidney disease: A post hoc analysis of the TEMPO 3:4 trial
It is unknown whether early diagnosis of autosomal dominant polycystic kidney disease (ADPKD) can enable earlier management and improve outcomes. We conducted a post hoc analysis of data from the TEMPO 3:4 trial. Subjects were stratified by ADPKD diagnosis at age ≤18 (childhood diagnosis [CD]) or>...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7062834/ https://www.ncbi.nlm.nih.gov/pubmed/32152377 http://dx.doi.org/10.1038/s41598-020-61303-9 |
_version_ | 1783504589698367488 |
---|---|
author | Janssens, Peter Jouret, François Bammens, Bert Liebau, Max C. Schaefer, Franz Dandurand, Ann Perrone, Ronald D. Müller, Roman-Ulrich Pao, Christina S. Mekahli, Djalila |
author_facet | Janssens, Peter Jouret, François Bammens, Bert Liebau, Max C. Schaefer, Franz Dandurand, Ann Perrone, Ronald D. Müller, Roman-Ulrich Pao, Christina S. Mekahli, Djalila |
author_sort | Janssens, Peter |
collection | PubMed |
description | It is unknown whether early diagnosis of autosomal dominant polycystic kidney disease (ADPKD) can enable earlier management and improve outcomes. We conducted a post hoc analysis of data from the TEMPO 3:4 trial. Subjects were stratified by ADPKD diagnosis at age ≤18 (childhood diagnosis [CD]) or>18 (adulthood diagnosis [AD]). Groups were compared for baseline characteristics and total kidney volume (TKV) growth and estimated glomerular filtration rate (eGFR) decline over 3 years. 294 CD and 1148 AD subjects were analyzed. At inclusion, CD subjects were younger (mean age 34.2 versus 39.8 years; p < 0.0001) and had better eGFR (mean ± SD 87.4 ± 23.9 versus 80.1 ± 20.7 mL/min/1.73 m(2); p < 0.0001), while CD had more severe Mayo risk classification (p < 0.0001) and more PKD1 mutations (p = 0.003). No statistical differences were found in TKV or eGFR change. At study end, placebo-treated CD subjects had better eGFR than projected by a prediction equation (mean difference ±SD for observed versus predicted eGFR: 2.18 ± 10.7 mL/min/1.73 m(2); p = 0.0475). However, these results are not confirmed when excluding stage 1 CKD. Whether CD subjects, despite their risk profile, have a slower disease course than predicted remains inconclusive. Future studies are needed to confirm that early diagnosis and management can alter the disease course of ADPKD. |
format | Online Article Text |
id | pubmed-7062834 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-70628342020-03-18 Implications of early diagnosis of autosomal dominant polycystic kidney disease: A post hoc analysis of the TEMPO 3:4 trial Janssens, Peter Jouret, François Bammens, Bert Liebau, Max C. Schaefer, Franz Dandurand, Ann Perrone, Ronald D. Müller, Roman-Ulrich Pao, Christina S. Mekahli, Djalila Sci Rep Article It is unknown whether early diagnosis of autosomal dominant polycystic kidney disease (ADPKD) can enable earlier management and improve outcomes. We conducted a post hoc analysis of data from the TEMPO 3:4 trial. Subjects were stratified by ADPKD diagnosis at age ≤18 (childhood diagnosis [CD]) or>18 (adulthood diagnosis [AD]). Groups were compared for baseline characteristics and total kidney volume (TKV) growth and estimated glomerular filtration rate (eGFR) decline over 3 years. 294 CD and 1148 AD subjects were analyzed. At inclusion, CD subjects were younger (mean age 34.2 versus 39.8 years; p < 0.0001) and had better eGFR (mean ± SD 87.4 ± 23.9 versus 80.1 ± 20.7 mL/min/1.73 m(2); p < 0.0001), while CD had more severe Mayo risk classification (p < 0.0001) and more PKD1 mutations (p = 0.003). No statistical differences were found in TKV or eGFR change. At study end, placebo-treated CD subjects had better eGFR than projected by a prediction equation (mean difference ±SD for observed versus predicted eGFR: 2.18 ± 10.7 mL/min/1.73 m(2); p = 0.0475). However, these results are not confirmed when excluding stage 1 CKD. Whether CD subjects, despite their risk profile, have a slower disease course than predicted remains inconclusive. Future studies are needed to confirm that early diagnosis and management can alter the disease course of ADPKD. Nature Publishing Group UK 2020-03-09 /pmc/articles/PMC7062834/ /pubmed/32152377 http://dx.doi.org/10.1038/s41598-020-61303-9 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Janssens, Peter Jouret, François Bammens, Bert Liebau, Max C. Schaefer, Franz Dandurand, Ann Perrone, Ronald D. Müller, Roman-Ulrich Pao, Christina S. Mekahli, Djalila Implications of early diagnosis of autosomal dominant polycystic kidney disease: A post hoc analysis of the TEMPO 3:4 trial |
title | Implications of early diagnosis of autosomal dominant polycystic kidney disease: A post hoc analysis of the TEMPO 3:4 trial |
title_full | Implications of early diagnosis of autosomal dominant polycystic kidney disease: A post hoc analysis of the TEMPO 3:4 trial |
title_fullStr | Implications of early diagnosis of autosomal dominant polycystic kidney disease: A post hoc analysis of the TEMPO 3:4 trial |
title_full_unstemmed | Implications of early diagnosis of autosomal dominant polycystic kidney disease: A post hoc analysis of the TEMPO 3:4 trial |
title_short | Implications of early diagnosis of autosomal dominant polycystic kidney disease: A post hoc analysis of the TEMPO 3:4 trial |
title_sort | implications of early diagnosis of autosomal dominant polycystic kidney disease: a post hoc analysis of the tempo 3:4 trial |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7062834/ https://www.ncbi.nlm.nih.gov/pubmed/32152377 http://dx.doi.org/10.1038/s41598-020-61303-9 |
work_keys_str_mv | AT janssenspeter implicationsofearlydiagnosisofautosomaldominantpolycystickidneydiseaseaposthocanalysisofthetempo34trial AT jouretfrancois implicationsofearlydiagnosisofautosomaldominantpolycystickidneydiseaseaposthocanalysisofthetempo34trial AT bammensbert implicationsofearlydiagnosisofautosomaldominantpolycystickidneydiseaseaposthocanalysisofthetempo34trial AT liebaumaxc implicationsofearlydiagnosisofautosomaldominantpolycystickidneydiseaseaposthocanalysisofthetempo34trial AT schaeferfranz implicationsofearlydiagnosisofautosomaldominantpolycystickidneydiseaseaposthocanalysisofthetempo34trial AT dandurandann implicationsofearlydiagnosisofautosomaldominantpolycystickidneydiseaseaposthocanalysisofthetempo34trial AT perroneronaldd implicationsofearlydiagnosisofautosomaldominantpolycystickidneydiseaseaposthocanalysisofthetempo34trial AT mullerromanulrich implicationsofearlydiagnosisofautosomaldominantpolycystickidneydiseaseaposthocanalysisofthetempo34trial AT paochristinas implicationsofearlydiagnosisofautosomaldominantpolycystickidneydiseaseaposthocanalysisofthetempo34trial AT mekahlidjalila implicationsofearlydiagnosisofautosomaldominantpolycystickidneydiseaseaposthocanalysisofthetempo34trial |